Torunn I. Yock

TL;DR: The use of proton radiation therapy was not associated with a significantly increased risk of secondary malignancies compared with photon therapy and longer follow-up of these patients is needed to determine if there is a significant decrease in second malignancy.

TL;DR: Proton radiotherapy resulted in acceptable toxicity and had similar survival outcomes to those noted with conventional radiotherapy, suggesting that the use of the treatment may be an alternative to photon-based treatments.

TL;DR: Current data do not provide sufficient evidence to recommend PBT in lung cancer, head and neck cancer, GI malignancies, and pediatric non-CNS malignancy, but there is evidence for the efficacy of PBT but no suggestion that it is superior to photon based approaches.

TL;DR: Preliminary disease control with proton therapy compares favorably with the literature and Dosimetric comparisons show the advantage of proton radiation compared with IMRT in the treatment of ependymoma.

TL;DR: An approach that uses next-generation sequencing to quantify the small fraction of DNA molecules that contain tumor-specific mutations within a background of normal DNA in plasma and shows the successful use of this method to follow treatment-associated changes in circulating tumor DNA levels in patients with non-small cell lung cancer.